How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium.

The Respond, Study Group (2020). How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. Microorganisms, 8(8) MDPI 10.3390/microorganisms8081164

[img]
Preview
Text
microorganisms-08-01164.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases.

METHODS

RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12.

RESULTS

Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438-830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events.

CONCLUSION

RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

ISSN:

2076-2607

Publisher:

MDPI

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

10 Sep 2020 07:58

Last Modified:

10 Sep 2020 07:58

Publisher DOI:

10.3390/microorganisms8081164

PubMed ID:

32752044

Additional Information:

Prof. Dr. med. Gilles Wandeler ist Mitglied der Forschungruppe "The Respond Study Group"

Uncontrolled Keywords:

HIV cohort hepatitis observational study pharmacovigilance public health tuberculosis

BORIS DOI:

10.7892/boris.146431

URI:

https://boris.unibe.ch/id/eprint/146431

Actions (login required)

Edit item Edit item
Provide Feedback